Advertisement Sorin Group and Greatbatch sign collaborative agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sorin Group and Greatbatch sign collaborative agreement

The Sorin Group and Greatbatch have executed a letter of intent that will leverage Greatbatch's eM-able technology in the Sorin Group's future cardiac rhythm management systems.

Magnetic resonance imaging (MRI) conditional approved devices are critical to allow patients with active implantable medical devices to safely have an MRI for diagnostic evaluation.

Catherine Picard, vice-president of R&D at Sorin Group, said: “We are very excited by the opportunity to leverage Greatbatch’s eM-able technology to accelerate our MRI program and deliver MRI conditional systems to patients and physicians worldwide in the shortest possible time.”